We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Leukocyte Ratio Predicts Ulcerative Colitis Severity

By LabMedica International staff writers
Posted on 11 Feb 2013
Print article
Blood neutrophil-to-lymphocyte (N/L) ratio is an indicator of the overall inflammatory status of the body, and an alteration in N/L ratio may be found in ulcerative colitis (UC) patients.

An optimal test has not yet been developed for UC and therefore the adjunctive use of additional blood markers may add a significant advantage for predicting disease severity and achieving diagnostic precision.

Medical scientists at Erciyes University (Kayseri, Turkey) enrolled 26 UC patients, 18 males and 8 females, and 28 healthy controls, 10 males and 18 females in the study. Complete blood counts, erythrocyte sedimentation rates (ESR), and C-reactive protein levels (CRP) were established for both patients and controls. The white blood count (WBC), neutrophil, and lymphocyte counts were recorded, and the N/L ratios were calculated from these parameters. The median disease duration in UC patients was 2.75 years.

The N/L ratios of patients with active UC were significantly higher at 3.85 ± 2.71 than those of inactive UC at 2.40 ± 1.05 and controls at 1.77 ± 0.68 were. The optimum N/L ratio cut-off point for active UC was 2.47. There was no significant difference between inflammation parameters, disease extension, and disease activity. The other inflammation markers such as ESR and CRP were also higher in the patients with active UC.

The authors concluded that in patients with UC, the N/L ratio is strongly associated with active disease. Unlike many other noninvasive markers of UC, the N/L ratio is inexpensive and readily available. Although the accuracy of the N/L ratio for detecting active UC is suboptimal, the ratio is an easily derived measure that might, in combination with other markers, assist in identifying patients at increased risk of active and severe disease. The study was published in the January 2013 issue of the Journal of Clinical Laboratory Analysis.

Related Links:

Erciyes University


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.